Posted on 10/01/2021 6:29:14 PM PDT by SeekAndFind
Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19.
If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, could be the first oral antiviral treatment for patients with COVID-19. Merck said it planned to seek emergency use authorization in the U.S. as soon as possible and added that it will also be submitting applications for the drug to "regulatory agencies worldwide."
The companies said that during a phase 3 trial, molnupiravir "significantly reduced the risk of hospitalization or death" in at-risk patients with mild or moderate cases of COVID-19.
The companies said that an interim analysis found that molnupiravir reduced the risk of hospitalization or death by approximately 50%.
According to the press release jointly issued by the two companies, "7.3 percent of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1 percent of placebo-treated patients (53/377)," the companies said.
The release added that no deaths were reported in patients treated with the new drug. In comparison, eight patients who received placebos died of COVID-19.
In a statement, Robert M. Davis, the chief executive officer and president of Merck, said that the company "will continue to work with regulatory agencies on our applications and do everything we can to bring molnupiravir to patients as quickly as possible."
Wendy Holman, the chief executive officer of Ridgeback Biotherapeutics, said that company hopes molnupiravir, if authorized, "can make a profound impact in controlling the pandemic."
(Excerpt) Read more at msn.com ...
Because the ivermectin patent expired 35 years ago? Thanks, Merck.
Is this the same as Ivermectin?
But they're vaxxshills on Twitter...
Since there is now an FDA approved vaccine (what a joke). There should be no more emergency authorizations. All new treatments should have to go through the normal (pre covid) approval process. We all know this will never happen.
“If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, could be the FIRST oral antiviral treatment for patients with COVID-19.”
Actually the second, and arguably the third.
RE: Is this the same as Ivermectin?
That’s what many suspect - an upgraded version of Ivermectin ( which they used to manufacture until the patent expired 35 years ago and it became generic ).
From what I'm reading, the big 3 Pharmaceutical companies are rolling out similar products.
Some are calling the Pfizer drug (because of its chemical similarity to Ivermectin) - Pfizermectin.
Different class. Same class as Remdesevir.
See link below...
https://covdb.stanford.edu/page/covid-review/#molnupiravir
Remdesivir.
I hate these bleeping names...
So $3 a pill or $300 a pill.
I used to have a Ford truck, but I put a Toyota emblem on it, so now it’s a Toyota.
this causes RAPID mutations in the virus.
DELTA will be nothing compared to what this will generate
from the millions of victims (petri dishes) who
will be VAX-RAPED.
I’ll opt for the horsey paste.
But then I’m a big fan of generics.
Tried being a lab rat once. Didn’t work out too well.
No, Ivermectin is a protease inhibitor. Merck’s drug is a ribonucleoside analog. It is the Pfizer pill that is a (different) protease inhibitor.
I don’t think any pregnant women were included in the trial. No heterosexual sex for women of child bearing age was allowed during the trial.
I remember it with the mnemonic “Run! Death is near”
Here is another difference. This is not being recommended as a preventative treatment. Ivermectin is.
Took another hit of Ivermectin tonight. It may need to protect against the molnupiravir.
Ivermectin with a patent.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.